PEPTIDES (peptides containing -lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D 519/02; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N 15/00)
| Subclass | Title |
|---|---|
| 1/00 | General processes for the preparation of peptides |
| 1/02 | General processes for the preparation of peptides in solution |
| 1/04 | General processes for the preparation of peptides on carriers |
| 1/06 | General processes for the preparation of peptides using protecting groups or activating agents |
| 1/08 | General processes for the preparation of peptides using protecting groups or activating agents using activating agents |
| 1/10 | General processes for the preparation of peptides using coupling agents |
| 1/107 | General processes for the preparation of peptides by chemical modification of precursor peptides |
| 1/113 | General processes for the preparation of peptides by chemical modification of precursor peptides without change of the primary structure |
| 1/12 | General processes for the preparation of peptides by hydrolysis |
| 1/13 | General processes for the preparation of peptides Labelling of peptides |
| 1/14 | General processes for the preparation of peptides Extraction; Separation; Purification |
| 1/16 | General processes for the preparation of peptides Extraction; Separation; Purification by chromatography |
| 1/18 | General processes for the preparation of peptides Extraction; Separation; Purification by chromatography Ion-exchange chromatography |
| 1/20 | General processes for the preparation of peptides Extraction; Separation; Purification by chromatography Partition-, reverse-phase or hydrophobic interaction chromatography |
| 1/22 | General processes for the preparation of peptides Extraction; Separation; Purification by chromatography Affinity chromatography or related techniques based upon selective absorption processes |
| 1/24 | General processes for the preparation of peptides Extraction; Separation; Purification by electrochemical means |
| 1/26 | General processes for the preparation of peptides Extraction; Separation; Purification by electrochemical means Electrophoresis |
| 1/28 | General processes for the preparation of peptides Extraction; Separation; Purification by electrochemical means Electrophoresis Isoelectric focusing |
| 1/30 | General processes for the preparation of peptides Extraction; Separation; Purification by precipitation |
| 1/32 | General processes for the preparation of peptides Extraction; Separation; Purification by precipitation as complexes |
| Patent # | Title | Filing Date | Issue Date | Patent Owner |
|---|---|---|---|---|
| RE49961 | Solid phase peptide syntheses | Nov 12, 20 | May 07, 24 | CEM Corporation |
| RE49936 | Beta-hexosyl-transferases and uses thereof | Dec 18, 20 | Apr 23, 24 | North Carolina State University |
| RE49918 | Cytotoxic benzodiazepine derivatives | May 10, 21 | Apr 16, 24 | Immunogen Inc. |
| Publication # | Title | Filing Date | Pub Date | Patent Owner |
|---|---|---|---|---|
| 2024/0147,971 | RODENTS HAVING A HUMANIZED TMPRSS GENE | Jan 16, 24 | May 09, 24 | Regeneron Pharmaceuticals, Inc. |
| 2024/0147,984 | COMPOSITIONS FOR EX VIVO ORGAN CARE | Mar 03, 22 | May 09, 24 | Not available |
| 2024/0148,569 | ABSORBENT STRUCTURE FOR ABSORBENT ARTICLES | Jan 18, 24 | May 09, 24 | Not available |
| 2024/0148,725 | COMBINATIONS FOR TREATMENT OF CANCERS RESISTANT TO EGFR-TARGETED THERAPIES | Nov 03, 23 | May 09, 24 | Not available |
| 2024/0148,740 | COMBINATION OF AN AHR INHIBITOR WITH A PDX INHIBITOR OR DOXORUBICINE | Oct 28, 21 | May 09, 24 | Not available |
| 2024/0148,771 | COMPOSITIONS AND METHODS FOR MODIFYING A PREDETERMINED TARGET NUCLEIC ACID SEQUENCE | May 15, 23 | May 09, 24 | TARGETGENE BIOTECHNOLOGIES LTD. |
| 2024/0148,785 | THERAPEUTIC CELL COMPOSITIONS AND METHODS FOR MANUFACTURE AND USES THEREOF | Nov 02, 23 | May 09, 24 | Not available |
| 2024/0148,787 | CO-EXPRESSED CXCR2 AND T CELLS OF STAR SPECIFIC TO GPC3, AND USE THEREOF | Feb 23, 22 | May 09, 24 | Not available |
| 2024/0148,789 | Synergistic Inhibition of eIF5A and Notch Signaling | Jul 17, 23 | May 09, 24 | The University of Toledo |
| 2024/0148,791 | COMPOSITIONS AND METHODS FOR ASSESSING AND TREATING T CELL DYSFUNCTION | Mar 08, 22 | May 09, 24 | Not available |
| 2024/0148,806 | BACTERIOPHAGES PRODUCING HETEROLOGOUS BACTERIOCINS | Jun 30, 23 | May 09, 24 | ETH Zurich |
| 2024/0148,809 | CANNABIS PREVENTS NK INACTIVATION IN CANCER AND INCREASES NK FUNCTION | Sep 09, 21 | May 09, 24 | Not available |
| 2024/0148,821 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | May 06, 22 | May 09, 24 | Not available |
| 2024/0148,824 | FIBROBLAST BINDING AGENTS AND USE THEREOF | Jan 02, 24 | May 09, 24 | Not available |
| 2024/0148,826 | CHIMERIC ANTIGEN RECEPTORS AND METHODS FOR REDUCING TOXICITY | Jun 05, 23 | May 09, 24 | Not available |
| 2024/0148,828 | GAMMA DELTA T-CELL COSTIMULATION | Mar 16, 22 | May 09, 24 | Not available |
| 2024/0148,839 | MODIFIED HUMAN SERUM ALBUMIN-THIOREDOXIN FUSION BODY | Mar 15, 22 | May 09, 24 | Not available |
| 2024/0148,841 | COMPOSITIONS AND METHODS RELATED TO IMMUNOGLOBULIN PROTEASES AND FUSIONS THEREOF | Aug 11, 23 | May 09, 24 | Not available |
| 2024/0148,843 | Peptide | Aug 11, 23 | May 09, 24 | Not available |
| 2024/0148,845 | GENETICALLY MODIFIED ANTI-THIRD PARTY CENTRAL MEMORY T CELLS AND USE OF SAME IN IMMUNOTHERAPY | Nov 21, 23 | May 09, 24 | Yeda Research and Development Co. Ltd. |
| Upgrade to the Professional Level to view Top Owners for this Class.Learn More |
|---|
